MOESM5 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Additional file 5: Figure S5. Forest plot of the long-term prognostic outcomes of anti-CTLA-4 therapy (Light smoker vs.Heavy smoker), PNon-smoker=0.670, PSmoker=0.820.